Margot Molander
Process Development Scientist Bristol Myers Squibb
Margot Molander is a Process Development scientist at Bristol Myers Squibb (BMS), where she supports a clinical-stage therapy currently manufactured through a manual process. As a key member of the automation integration team, Margot works closely with an original equipment manufacturer to design and implement a fully automated, custom-built manufacturing system. Her work focuses on translating an established manual process into an automated platform while maintaining process comparability and regulatory alignment. With hands-on experience in custom equipment integration and agency-ready strategy, she helps enable seamless evolution from clinical manufacturing to scalable automation.
Seminars
Wednesday 15th July 2026
Strategically Integrating Automation from Manual Processes to Avoid Pitfalls & Balance Custom Development with Existing Technologies
4:10 pm
- Addressing the cell therapy automation paradox by determining optimal implementation timing since fully automated closed systems remain expensive and impractical for early research-scale development
- Balancing custom automation development versus leveraging existing unit operation technologies to avoid reinventing the wheel while maintaining regulatory and business viability
- Securing full organizational buy-in and strategic planning upfront to prevent late-stage automation failures from agency requirements or internal business challenges after significant investment
Thursday 16th July 2026
Panel Discussion: Building Strategic Vendor Partnerships to Support Seamless Progression from Clinical Development to Commercial Manufacturing
11:00 am
- Selecting vendors with proven capability to scale support from early clinical phases through commercial launch and beyond
- Conducting comprehensive due diligence to evaluate vendor reliability, regulatory compliance, and long-term partnership potential amid evolving market complexities
- Collaborating with automation vendors early in product development to influence their pipelines and ensure tools meet specific biotechnology requirements
